Hemlibra worked better than immune tolerance induction to control bleeding in children with severe hemophilia A with inhibitors, per a study.

Three years after the FDA forced Novo Nordisk to pause a trial of its potential Hemlibra rival over reports of blood clots, the U.S. regulator has placed further barriers in front of the drug—even as ...